Here are the DEF 14A proxy statements from Editas Medicine, Inc. (EDIT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow EDIT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EDIT filings page.
Editas Medicine has issued its definitive proxy statement for the 2026 virtual annual meeting on June 17, 2026, where stockholders will elect two Class I directors, cast an advisory vote on executive pay, and ratify PricewaterhouseCoopers as auditor.
The company highlights its strategic shift to a fully in vivo gene editing preclinical model, including lead candidate EDIT-401 for LDL‑cholesterol with preclinical LDL‑C reductions exceeding 90% in non‑human primates. Management reports extending its cash runway into the third quarter of 2027, supported in part by an at‑the‑market offering program.
Governance and pay practices emphasize board independence, a separate chair and CEO, annual say‑on‑pay, anti‑hedging and clawback policies, and substantial performance-based pay, with approximately 73% of CEO target compensation and 54% of other named executive officer target compensation designated as performance-based. The board determined 2025 corporate objectives were achieved at 91% of target for bonus purposes and is recommending stockholders vote in favor of all three proposals.